This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PharmGKB | |
|---|---|
| Name | PharmGKB |
| Type | Database |
| Established | 2000 |
| Focus | Pharmacogenomics, pharmacogenetics, drug–gene interactions |
| Country | United States |
| Host | Stanford University (original) |
| Website | PharmGKB |
PharmGKB
PharmGKB is a pharmacogenomics knowledge resource integrating information about how human genetic variation affects drug response, linking genetic variants to drug efficacy, toxicity, and dosing. Founded at an academic center and developed through collaborations among researchers, clinicians, and regulatory agencies, it aggregates curated literature, pathway maps, and clinical annotations to support precision medicine efforts across pharmacology and genomics communities.
PharmGKB compiles curated data on drug–gene relationships, variant annotations, clinical guidelines, and pharmacokinetic and pharmacodynamic pathways, serving researchers, clinicians, and policy makers. It connects literature findings with translational resources and aligns with clinical resources such as Food and Drug Administration, Clinical Pharmacogenetics Implementation Consortium, and European Medicines Agency. The resource interoperates with genomic repositories and standards organizations including dbSNP, ClinVar, National Center for Biotechnology Information, Genome-wide Association Study Catalog, and Global Alliance for Genomics and Health, and informs initiatives by institutions like National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, and National Human Genome Research Institute.
PharmGKB originated in the early 2000s at an academic institution and expanded through partnerships with consortia, foundations, and government programs. Early influences included projects and organizations such as Human Genome Project, International HapMap Project, 1000 Genomes Project, and collaborations with centers like Stanford University School of Medicine, University of California, Massachusetts General Hospital, and Mayo Clinic. Funding and strategic partnerships involved entities such as National Institutes of Health, National Institute of General Medical Sciences, Department of Veterans Affairs, and philanthropic groups like Howard Hughes Medical Institute and Wellcome Trust. Over time, the resource incorporated community-driven standards from groups such as Global Alliance for Genomics and Health and technical standards from HL7 and Clinical Data Interchange Standards Consortium.
PharmGKB curators extract and synthesize evidence from peer-reviewed literature, clinical trials, and regulatory labels, generating variant annotations, drug summaries, and clinical annotations tied to alleles and haplotypes. It cross-references variant identifiers from databases such as dbSNP, Ensembl, RefSeq, and UniProt and maps drugs to vocabularies including RxNorm and Anatomical Therapeutic Chemical Classification System. Curatorial practices align with reporting standards promoted by organizations like CONSORT, STARD, and PRISMA for reproducible evidence synthesis. Content includes pathways developed alongside research groups at institutions such as Broad Institute, Cold Spring Harbor Laboratory, Salk Institute, and Johns Hopkins University.
PharmGKB offers web-based interfaces, downloadable datasets, APIs, and visualization tools for pathways, genotype–phenotype relationships, and evidence grading. It integrates with bioinformatics tools and platforms such as UCSC Genome Browser, Ensembl Genome Browser, Galaxy Project, Bioconductor, and GATK to facilitate analysis workflows. APIs and data formats align with community standards promoted by organizations including Global Alliance for Genomics and Health, HL7 FHIR, and JSON, enabling interoperability with electronic health record systems used by institutions like Kaiser Permanente, Cleveland Clinic, and Veterans Health Administration.
PharmGKB informs clinical guidelines, dosing recommendations, and decision support systems used in translational programs and healthcare settings, supporting guideline development by groups such as Clinical Pharmacogenetics Implementation Consortium, Dutch Pharmacogenetics Working Group, and regulatory decisions by Food and Drug Administration and European Medicines Agency. Implementation examples involve integration with electronic prescribing and clinical decision support at centers like Mayo Clinic, Massachusetts General Hospital, University of Chicago Medicine, and regional health systems including Geisinger Health System and Intermountain Healthcare. The knowledgebase contributes to educational efforts at universities and professional societies such as American College of Medical Genetics and Genomics, American Society of Human Genetics, European Society of Pharmacogenomics and Personalized Therapy, and it informs translational research in consortia like eMERGE Network, All of Us Research Program, 100,000 Genomes Project, and UK Biobank.
Governance structures combine academic leadership, advisory boards, and partnerships with funding bodies including National Institutes of Health, National Human Genome Research Institute, National Institute of General Medical Sciences, private foundations such as Howard Hughes Medical Institute and Gordon and Betty Moore Foundation, and collaborative funding from industry partners and consortia. Oversight and ethical frameworks reference guidance from institutions like Office for Human Research Protections, World Health Organization, and standards bodies including Global Alliance for Genomics and Health and Council for International Organizations of Medical Sciences.
Category:Pharmacogenomics